(HKSE:6855),(NasdaqGM:AAPG), Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option Lisaftoclax achieved a 62.5% objective response rate (ORR) in heavily pretreated, BTKi-refractory patients, nearly half with complex karyotype Lisaftoclax monotherapy demonstrated a median progression-free […]

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting GlobeNewswire December 06, 2025 Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment

NEW YORK, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Logitech International S.A. ("Logitech" or the "Company") (NASDAQ:LOGI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Logitech and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ:RGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Regencell and certain of its officers

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Plug Power Inc. ("Plug" or the "Company") (NASDAQ:PLUG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Plug and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ:OM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Outset Medical and certain of its

Lakewood Ranch, Dec. 06, 2025 (GLOBE NEWSWIRE) — JCBC Publishing, LLC, a distinguished name in the literary world, proudly announces the upcoming release of 'That Kind of Girl,' the debut novel by Jacey Bici, set to launch in 2025. Jacey Bici, a practicing physician and mother, writes under a pseudonym, drawing inspiration from her rich

JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025 Celebrated physician and author Jacey Bici unveils her first women's fiction novel, exploring transformative moments in women's lives. GlobeNewswire December 06, 2025 Lakewood Ranch, Dec. 06, 2025 (GLOBE NEWSWIRE) — JCBC Publishing, LLC, a distinguished name in the literary

(NYSE:PRGO), SAN DIEGO, Dec. 06, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Perrigo Company plc (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, all dates inclusive (the “Class Period”), have until January 16, 2026 to seek appointment as lead plaintiff of the Perrigo

PRGO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit GlobeNewswire December 06, 2025 SAN DIEGO, Dec. 06, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Perrigo Company plc (NYSE: PRGO)